
LluÃ-s Castells Fusté

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5589008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. New England Journal of Medicine, 1999, 341, 403-409.	13.9	1,519
2	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. Journal of Hepatology, 2007, 46, 474-481.	1.8	864
3	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. Journal of Hepatology, 2021, 74, 148-155.	1.8	261
4	Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology, 2003, 38, 51-58.	1.8	212
5	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology, 2015, 61, 1485-1494.	3.6	206
6	Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transplantation, 2005, 11, 1242-1251.	1.3	189
7	Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of Hepatology, 2005, 43, 53-59.	1.8	148
8	Complications of Orthotopic Liver Transplantation: Spectrum of Findings with Helical CT. Radiographics, 2001, 21, 1085-1102.	1.4	145
9	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. Gastroenterology, 2021, 160, 1151-1163.e3.	0.6	130
10	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. Journal of Hepatology, 2017, 67, 1168-1176.	1.8	96
11	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. Journal of Hepatology, 2017, 66, 718-723.	1.8	90
12	Liver Transplantation for Malignant Diseases: Selection andPattern of Recurrence. World Journal of Surgery, 2002, 26, 257-263.	0.8	85
13	Single HCC in Cirrhotic Patients: Liver Resection or Liver Transplantation? Long-term Outcome According to an Intention-to-treat Basis. Annals of Surgical Oncology, 2013, 20, 1194-1202.	0.7	83
14	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. Journal of Hepatology, 2018, 69, 11-17.	1.8	80
15	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for endâ€stage liver disease: Analysis of data from the Hepa registry. Hepatology, 2017, 65, 1810-1822.	3.6	78
16	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. Journal of Clinical Microbiology, 2015, 53, 219-226.	1.8	74
17	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation, 2016, 22, 446-458.	1.3	73
18	COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. The Lancet Gastroenterology and Hepatology, 2020, 5, 724-725.	3.7	72

LLUÃS CASTELLS FUSTé

#	Article	IF	CITATIONS
19	A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transplant International, 2005, 18, 1336-1345.	0.8	58
20	Sofosbuvir/velpatasvir for 12†weeks in genotype 1–4 HCV-infected liver transplant recipients. Journal of Hepatology, 2018, 69, 603-607.	1.8	58
21	COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management. Transplantation, 2021, 105, 138-150.	0.5	50
22	Cirrhosis, Liver Transplantation and HIV Infection Are Risk Factors Associated with Hepatitis E Virus Infection. PLoS ONE, 2014, 9, e103028.	1.1	46
23	Hemoperitoneum as a first manifestation of hepatocellular carcinoma in western patients with liver cirrhosis: effectiveness of emergency treatment with transcatheter arterial embolization. Digestive Diseases and Sciences, 2001, 46, 555-562.	1.1	43
24	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	1.9	39
25	Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transplantation, 2012, 18, 201-205.	1.3	34
26	Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation, 2002, 8, 892-900.	1.3	33
27	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. American Journal of Transplantation, 2021, 21, 2876-2884.	2.6	32
28	Liver Transplantation in HIV-HCV Coinfected Patients: A Case-Control Study. Transplantation, 2007, 83, 354-358.	0.5	31
29	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology, 2016, 63, 488-498.	3.6	27
30	Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. Infection and Drug Resistance, 2018, Volume 11, 2207-2210.	1.1	26
31	Visceral leishmaniasis among liver transplant recipients: An overview. Liver Transplantation, 2008, 14, 1816-1819.	1.3	25
32	A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. Journal of Hepatology, 2021, 75, 275-283.	1.8	23
33	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. Antiviral Therapy, 2006, 11, 1061-1070.	0.6	23
34	Safety of liver transplantation with chagas disease-seropositive donors for seronegative recipients. Liver Transplantation, 2011, 17, 1304-1308.	1.3	22
35	Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. Journal of Hepatology, 2015, 62, 92-100.	1.8	20
36	Recurrent hepatitis C virus infection after liver transplantation: Immunohistochemical assessment of the viral antigen. Liver Transplantation, 1998, 4, 320-327.	1.9	19

LLUÃS CASTELLS FUSTé

#	Article	IF	CITATIONS
37	Indocyanine green plasma disappearance rate: a new tool for the classification of paediatric patients with acute liver failure. Liver International, 2014, 34, 689-694.	1.9	19
38	Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant. Annals of Hepatology, 2017, 16, 86-93.	0.6	19
39	Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. Liver Transplantation, 2009, 15, 300-305.	1.3	18
40	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC Infectious Diseases, 2017, 17, 45.	1.3	17
41	Successful conversion from twiceâ€daily to onceâ€daily tacrolimus in liver transplantation: observational multicenter study. Clinical Transplantation, 2012, 26, E32-7.	0.8	16
42	Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study). Microbiology Spectrum, 2022, 10, e0178421.	1.2	16
43	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver International, 2018, 38, 1940-1950.	1.9	15
44	Role of Biodegradable Stents as Part of Treatment of Biliary Strictures after Pediatric and Adult Liver Transplantation: An Observational Single-Center Study. Journal of Vascular and Interventional Radiology, 2018, 29, 899-904.	0.2	12
45	Imaging of hepatitis C virus infection in liver grafts after liver transplantation. Journal of Hepatology, 2013, 59, 271-278.	1.8	10
46	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver International, 2017, 37, 1823-1832.	1.9	10
47	Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: Report of two cases and comprehensive review of the literature. Transplant Infectious Disease, 2019, 21, e13072.	0.7	10
48	Decreased Longâ€Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. Liver Transplantation, 2022, 28, 1039-1050.	1.3	9
49	Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study. Transplant International, 2018, 31, 38-44.	0.8	8
50	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. Transplant International, 2003, 16, 270-275.	0.8	7
51	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. GastroenterologĂa Y HepatologÃa, 2017, 40, 515-524.	0.2	7
52	High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation. Clinical and Translational Science, 2022, 15, 1544-1555.	1.5	7
53	Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation. Liver Transplantation, 2011, 17, 1474-1480.	1.3	6
54	Twelve-Week Posttreatment Follow-Up to Predict Sustained Virologic Response for Recurrent Hepatitis C Infection in Liver Recipients. Transplantation, 2012, 93, 450-453.	0.5	6

LluÃs Castells Fusté

#	Article	IF	CITATIONS
55	Successful Continuation of HCV Treatment After Liver Transplantation. Transplantation, 2017, 101, 1009-1012.	0.5	6
56	Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transplant International, 2017, 30, 1041-1050.	0.8	6
57	Low Total Dose of Anti-Human T-Lymphocyte Globulin (ATG) Guarantees a Good Glomerular Filtration Rate after Liver Transplant in Recipients with Pretransplant Renal Dysfunction. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-7.	0.8	6
58	Recipient Age for Liver Transplantation: Should It Be Limited? A Propensity Score Matching Analysis of a Large European Series. Transplantation Proceedings, 2020, 52, 1442-1449.	0.3	6
59	Reconciling shortâ€ŧerm clinical and Immunological outcomes of SARS oVâ€2 vaccination in Solid Organ Transplant recipients. American Journal of Transplantation, 2021, , .	2.6	6
60	Does Matching Donor-Recipient Age Affect Long-Term Survival in Liver Transplantation?. Annals of Transplantation, 2016, 21, 708-716.	0.5	6
61	Spontaneous portosystemic shunt embolization in liver transplant recipients with recurrent hepatic encephalopathy. Annals of Hepatology, 2022, 27, 100687.	0.6	6
62	Liver biopsy-related infection in liver transplant recipients: A current matter of concern?. Liver Transplantation, 2014, 20, 552-556.	1.3	5
63	Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: A cohort study. Liver Transplantation, 2014, 20, 856-863.	1.3	5
64	Routine Bile Culture From Liver Donors as Screening of Donorâ€Transmitted Infections in Liver Transplantation. Liver Transplantation, 2020, 26, 1121-1126.	1.3	4
65	Isolated bilateral Tapia's syndrome after liver transplantation: A case report and review of the literature. World Journal of Hepatology, 2016, 8, 1637.	0.8	4
66	Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. Liver Transplantation, 2017, 23, 645-651.	1.3	3
67	Does Routine Abdominal Drain Tip Culture Anticipate Post-Operative Infection in Liver Transplantation?. Surgical Infections, 2021, 22, 222-226.	0.7	3
68	Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. Journal of Clinical Medicine, 2022, 11, 2466.	1.0	3
69	Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. Hepatology, 2019, 69, 2701-2703.	3.6	2
70	Transition to Adult Care for Pediatric Liver Transplant Recipients. Transplantation Proceedings, 2020, 52, 1496-1499.	0.3	2
71	Longâ€ŧerm effects of COVIDâ€19 in solid organ transplantation recipients. Transplant Infectious Disease, 2021, 23, e13677.	0.7	2
72	Low seroprevalence of SARS oVâ€2 antibodies in a liver transplant cohort. Transplant International, 2021, 34, 1908-1913.	0.8	2

#	Article	IF	CITATIONS
73	Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study. Liver Transplantation, 2022, 28, 1257-1261.	1.3	2
74	Arterialización de la vena porta en el trasplante hepático humano. CirugÃa Española, 2002, 72, 169-174.	0.1	0
75	Prevention and treatment of hepatitis B virus recurrence after liver transplantation. Current Opinion in Organ Transplantation, 2006, 11, 589-593.	0.8	0
76	Corrigendum to "Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study―[J Hepatol 2015;62:92–100]. Journal of Hepatology, 2016, 64, 757.	1.8	0
77	Derrame pleural izquierdo secundario a infartos esplénicos en una paciente con cirrosis hepática. Medicina ClÃnica, 2017, 148, 144-145.	0.3	0